aTyr Pharma, Inc.
ATYR
$0.53
-$0.03-5.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 190.00K | 190.00K | 190.00K | 0.00 | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 190.00K | 190.00K | 190.00K | 0.00 | 0.00 |
| Cost of Revenue | 55.72M | 60.22M | 61.56M | 54.23M | 52.82M |
| Gross Profit | -55.53M | -60.03M | -61.37M | -54.23M | -52.82M |
| SG&A Expenses | 17.76M | 17.60M | 17.29M | 15.82M | 14.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.48M | 77.82M | 78.84M | 70.05M | 67.05M |
| Operating Income | -73.29M | -77.63M | -78.65M | -70.05M | -67.05M |
| Income Before Tax | -70.03M | -74.12M | -75.13M | -66.64M | -63.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -70.03 | -74.12 | -75.13 | -66.64 | -63.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 5.00K | 5.00K | 5.00K | 5.00K | 4.00K |
| Net Income | -70.03M | -74.12M | -75.12M | -66.64M | -63.41M |
| EBIT | -73.29M | -77.63M | -78.65M | -70.05M | -67.05M |
| EBITDA | -72.63M | -76.96M | -77.98M | -69.36M | -66.35M |
| EPS Basic | -0.73 | -0.80 | -0.83 | -0.80 | -0.81 |
| Normalized Basic EPS | -0.46 | -0.50 | -0.52 | -0.50 | -0.50 |
| EPS Diluted | -0.73 | -0.80 | -0.83 | -0.80 | -0.81 |
| Normalized Diluted EPS | -0.46 | -0.50 | -0.52 | -0.50 | -0.50 |
| Average Basic Shares Outstanding | 383.33M | 371.77M | 356.48M | 335.13M | 317.30M |
| Average Diluted Shares Outstanding | 383.33M | 371.77M | 356.48M | 335.13M | 317.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |